Cytosolic GIVA phospholipase A2 (GIVA cPLA2) initiates the eicosanoid pathway of inflammation and thus inhibitors of this enzyme constitute novel potential agents for the treatment of inflammatory diseases. Traditionally, GIVA cPLA2 inhibitors have suffered systemically from high lipophilicity. We have developed a variety of long chain 2-oxoamides as inhibitors of GIVA PLA2. Among them, AX048 was found
胞质GIVA
磷脂酶A 2(GIVA cP
LA 2)引发炎症的类
二十烷酸途径,因此该酶的
抑制剂构成了治疗炎症性疾病的新型潜在药物。传统上,GIVA cP
LA 2
抑制剂全身性地具有高亲脂性。我们已经开发出多种长链2-氧代酰胺作为GIVA P
LA 2的
抑制剂。其中,发现AX048产生有效的止痛作用。现在,我们通过将长脂肪链替换为含有醚连接的芳香环的链来降低AX048的亲脂性,该链具有类似于AX048的体外抑制活性。